Grifols introduces its first plasma protein-based biosurgery product

• VISTASEAL^™, a fibrin sealant developed by Grifols for biosurgical bleeding-control, is marketed and distributed by Ethicon and is the result of the two companies’ strategic collaboration
• VISTASEAL^™ contains a combination of two plasma proteins (fibrinogen and thrombin) administered with Ethicon’s innovative device

Barcelona, Spain, December 4, 2019 – Grifols, (MCE: GRF; MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with more than 100 years dedicated to enhancing people’s health and well-being and a leader in plasma medicines, transfusion diagnosis and pharmaceutical specialties for hospital use, today introduced VISTASEAL^™, its first plasma-protein-based biosurgery solution.

VISTASEAL^™ is a fibrin sealant for surgical bleeding-control that combines two plasma proteins (fibrinogen and thrombin) administered with Ethicon’s airless spray device technology.

The collaboration combines Grifols’ ability to produce critical plasma-based therapies with Ethicon’s expertise in developing device technology. Ethicon, a Johnson & Johnson Medical Devices Company, is commercializing and distributing VISTASEAL^™ in the U.S.

Eduardo Herrero, President Grifols Bioscience Industrial Group, said: “VISTASEAL^™ is the result of our continuous efforts to innovate and a commitment to in-house R&D projects. We will continue to investigate and explore different areas of medicine with unmet needs in which plasma proteins can add value. In this sense, biosurgery is a field full of potential for us in which we count on a sound, strategic ally in Ethicon.”

The VISTASEAL^™ biological components are produced in the industrial complex of Parets del Vallés (Barcelona, Spain), which has a production capacity of over 300,000 units, as well as capacity to expand to 3 million equivalent liters of plasma.

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Phone number: +34 93 571 02 21

Media contacts:

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.